
Jasper Therapeutics (JSPR) Stock Forecast & Price Target
Jasper Therapeutics (JSPR) Analyst Ratings
Bulls say
Jasper Therapeutics Inc is advancing its innovative hematopoietic stem cell therapies, demonstrating promising efficacy with an impressive 89% complete response (CR) rate across two dosing cohorts, highlighting the potential effectiveness of its treatment options. The company's focus on safer and more effective conditioning agents positions it favorably within the biotechnology sector, particularly as it seeks to expand the use of stem cell transplantation and gene therapy. Additionally, the differentiation of its lead product, briquilimab, through its shorter half-life may offer competitive advantages in safety and patient outcomes compared to existing therapies.
Bears say
Jasper Therapeutics has experienced a notable decline in stock value due to complications surrounding a faulty drug lot for briquilimab, which has also led to a pause in the ETESIAN trial for asthma. Additionally, the company raised $30 million through common stock and pre-funded warrants, which may indicate financial distress and a need for liquidity. The updated diluted share count has further pressured the stock price, leading to a significant downward revision of the company's price target from $20 to $7.
This aggregate rating is based on analysts' research of Jasper Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Jasper Therapeutics (JSPR) Analyst Forecast & Price Prediction
Start investing in Jasper Therapeutics (JSPR)
Order type
Buy in
Order amount
Est. shares
0 shares